OMEGA-3 ACID CAP,ORAL
Clinical Criteria Summary
Indication
- Severe hypertriglyceridemia
Laboratory Criteria
- Fasting triglyceride level of > 500 mg/dL on two occasions
Pre-treatment Considerations & Warnings
- Secondary causes should be considered and addressed prior to initiation of therapy
- Effect of Lovaza and Lovaza generics on risk for pancreatitis in patients with severe hypertriglyceridemia has not been established
Therapeutic Efficacy & Alternatives
- Evidence does not support a greater triglyceride lowering response between Lovaza, Lovaza generics and icosapent ethyl
- For patients who may be candidates for reducing cardiovascular (CV) risk with icosapent ethyl (established CV disease, on statins with LDL 41-100 mg/dL and fasting TG > 150 mg/dL), refer to CFU for Icosapent Ethyl